Adverse events following COVID-19 vaccination in Kwara State, North-central Nigeria

Odeigah, Louis O.; Mutalub, Yahkub Babatunde; Agede, Olalekan Ayodele; Obalowu, Ismail A.; Aiyetoro, Susan; Jimoh, Gafar A. A.

doi:10.1371/journal.pgph.0000835

Cited by 4 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A larger number of the respondents were females (70.4%), which agrees with the survey data of COVID-19 vaccine adverse events among hospital staff in a national referral hospital in Indonesia by Djanas et al (2021), where females had the highest number of participants. However, this study was contrary to the study by Odeigah et al (2022) where males accounted for 64.3%. In this study, most of the health workers (50.3%) were aged between 31 and 40.…”

Section: Discussioncontrasting

confidence: 99%

Adverse events following administration of COVID-19 vaccine among health workers in Kwara State, North Central Nigeria

Bello,

Adepoju,

Aliyu

et al. 2024

njpr

View full text Add to dashboard Cite

Background: The Coronavirus disease 2019 (COVID-19) pandemic has been a health issue of great concern. The disease has caused a substantial reduction in the workforce globally. In 2020, several vaccines were approved to prevent COVID-19 infection.Objective: This study evaluated adverse events following the administration of the COVID-19 vaccine among secondary healthcare workers in Kwara State, NigeriaMethods: This was a multicenter, and cross-sectional study conducted in eleven secondary healthcare hospitals among 348 health workers using a validated questionnaire. Ethical approval and informed consent were obtained appropriately. The questionnaire was read, explained, and distributed to the respondents at each facility between December 2022 and June 2023. The forms were filled out accordingly. Appropriate statistical software was used to analyze the collected data.Results: Among the 348 respondents studied, most were females (70.4%) within the age range of 31-40 years (50.3%). Few (16.4%) of the respondents were infected, however, the majority (62.9%) were fully vaccinated. Approximately one-third (31.1%) received the AstraZeneca vaccine. The most commonly experienced adverse events were fever (34.2%), headache (33.9%), tiredness (31.0%), and general body pain (30.3%). There was a significant association between the type of vaccine administered, dose received, and adverse events experienced at p < 0.05. In addition, there was a significant correlation between adverse events and the gender of the respondents at p < 0.05.Conclusion: Some respondents experienced adverse events after administration of COVID-19 vaccination. These events were associated with the type of vaccine, dose of vaccine received, and gender.

show abstract

Section: Discussioncontrasting

confidence: 99%

Adverse events following administration of COVID-19 vaccine among health workers in Kwara State, North Central Nigeria

Bello,

Adepoju,

Aliyu

et al. 2024

njpr

View full text Add to dashboard Cite

show abstract

“…No significant relationship was observed between age and gender and occurrence of AEs. This is similar to the finding by Odeigah et al [38] Osibogun et al in their study however observed that the older age group(>60 years) had a lower likelihood for COVID-19 Vaccine AEs compared with the 18-24 years age group [28]. In this study, there was also no significant association between the occurrence of AEs and the sociodemographic variables of respondents.…”

Section: Discussionsupporting

confidence: 91%

“…The study done in Yenogoa, South-South Nigeria revealed pain at injection site as the commonest symptom followed by headache and fatigue [35]. Previous studies also have similar findings [31][32][33][38][39][40].…”

Section: Discussionmentioning

confidence: 77%

Adverse Events Following COVID-19 Vaccination in Anambra State, South East Nigeria

L.,

Eze,

et al. 2023

AJMAH

View full text Add to dashboard Cite

The use of safe and effective vaccination is critical to control of pandemics. Vaccines remain the bedrock in management of infectious diseases outbreaks. There has always been hesitancy to vaccination due to the fear of adverse events. It is therefore necessary that post vaccination adverse events be studied for effective enlightenment of the general populace. Objective: We aimed to investigate the adverse reactions following COVID-19 vaccination in Anambra state, South East Nigeria. Methods: Using a cross-sectional study design, 433 subjects aged 18years or older who had received any dose of the four COVID-19 vaccines (Moderna, Astra Zeneca, Pfizer and J&J (Janssen) were selected using a multi-stage sampling technique. The subjects were interviewed about COVID-19 vaccine related adverse reactions using self-administered questionnaire. Descriptive statistics (mean, standard deviation) and analytical statistics were performed and level of significance set at < 0.5 using SPSS V24. Results: Of the 433 subjects finally studied, 62.8% were females and 22.4% were married. About 69% of them had tertiary education. Those who received the second dose of their respective vaccines were 44.8% while 11.5% had received a booster dose. Approximately half (50.3%) of the COVID-19 vaccines had adverse events. The most common types of adverse events (AEs) were local pain at injection site (62.1%) followed by headache (54.3%) and then fatigue (50.1%). Majority of the adverse events were mild to moderate in severity. Those who had only local adverse events were 70.2% while 45% had systemic adverse events. Conclusion: In this study, severe adverse events were rare, even after the second dose. Most of the adverse events were mild to moderate in severity and therefore awareness campaign should be created to enlighten the community about the adverse effects of COVID-19 vaccines.

show abstract

Safety and Immunogenicity of Fractional Doses of COVID-19 Vaccines among Nigerian Adults- A Randomised Non-Inferiority trial

Olurotimi,

Zaidat,

Anthonia

et al. 2024

Preprint

View full text Add to dashboard Cite

The shortage of COVID-19 vaccines posed a significant challenge in optimal response to the COVID-19 pandemic. Fractional doses of vaccine with adequate immunogenic response and proven safety profile emerged as potential strategy to extend the limited vaccine doses. This study was aimed to evaluate the immunogenicity and safety of fractional doses of the ChadOx1, Ad26.COV2.S, and BNT162B2 vaccines among healthy Nigerian adults. A non-inferiority multi-site triple-blind clinical trial was undertaken in Nigeria. Healthy Nigerian adults (18-65 years) who met the inclusion criteria were enrolled in the study. Participants were block-randomized into three vaccine arms (ChadOx1 quarter, half, and full dose; Ad26.COV2.S: quarter, half and full dose; and BNT162B2: half and full dose) . Participants, clinical staff (clinicians and nurses) and laboratory personnel were blinded. The primary objective of the study was to evaluate non-inferiority in seroconversion rates, defined as geometric mean fold rise (GMFR) ≥ 2.5 in serum anti-spike IgG titre at 28 days post-vaccination by ELISA. Immunogenicity analysis included use of serum neutralization assays using pseudotyped virus bearing spike from Wu-1 and Omicron variants. A total of 1891 participants were enrolled between June 21, 2022, and January 25, 2023. 320 participants in the fractional dose group and 220 in the standard dose group completed follow-up and were included in the analysis. SARS-CoV-2 seropositivity at baseline was high, at 68% (365/539). Seroconversion (geometric mean fold rise) was comparable between standard and fractional doses. For ChAdOx1, 31% achieved ≥ 2.5 fold change increase in serum binding antibody in the standard dose arm (16/52), 28% in half dose (15/53), and 34% in quarter dose (18/53). For Ad26.COV2.S, the proportions were 27% (28/105) in standard dose, 32% (22/68) in half dose, and 30% (21/71) in quarter dose arms respectively. For BNT162N2, the proportions were 43% (27/63) in standard dose and 39% (29/75) in half dose. Subset analysis of binding and neutralization responses in (n=64) participants demonstrated high degree of of prior exposure to SARS-CoV-2 ancestral and Omicron lineage variants prior to vaccination. Serum neutralization responses showed ≥2-fold response to both full and fractional doses indicating immunogenic responses to the vaccine dosing regimens. There was no report of serious adverse events. Fractional vaccine doses showed potential to generate non-inferior immune responses compared to standard doses in the context of a population with high rate of previous exposure to SARS-CoV-2 infection. The three vaccines are safe and well tolerated. Fractional dose should be considered to boost herd immunity and prevent outbreaks of SARS-COV-2.

show abstract

Adverse events following COVID-19 vaccination in Kwara State, North-central Nigeria

Cited by 4 publications

References 20 publications

Adverse events following administration of COVID-19 vaccine among health workers in Kwara State, North Central Nigeria

Adverse events following administration of COVID-19 vaccine among health workers in Kwara State, North Central Nigeria

Adverse Events Following COVID-19 Vaccination in Anambra State, South East Nigeria

Safety and Immunogenicity of Fractional Doses of COVID-19 Vaccines among Nigerian Adults- A Randomised Non-Inferiority trial

Contact Info

Product

Resources

About